Inspire Pharmaceuticals (Nasdaq: ISPH) grew its revenue 6 percent in the third quarter over a year ago, cutting its losses and beating Wall Street analysts’ expectations.
The company reported Thursday before the markets opened that it loss $7.6 million, or 9 cents per share.
Analysts polled by Thomson Reuters expected a 14 cent loss. A year ago, Inspire lost $8.5 million or 12 cents per share.
Revenues grew to $26.7 million with sales of the drug Azasite climbing 23 percent to $11.1 million. Royalties from the sale of Restasis grew to $11.7 million from $9.4 million.
For the full financial report,
Get the latest news alerts: at Twitter.